ModerateSerotonin antagonist and reuptake inhibitor (SARI) antidepressant×Antidepressant (other antidepressants, N06AX)
Updated · Methodology
Mechanism
Both drugs increase serotonin activity: trazodone inhibits serotonin reuptake, and vortioxetine is also an antidepressant with a serotonergic effect (trazodone summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS; vortioxetine SmPC, European Medicines Agency, EMA). Combining serotonergic drugs raises the risk of serotonin syndrome and neuroleptic malignant syndrome (trazodone SmPC, AEMPS; vortioxetine SmPC, EMA). Trazodone prolongs the QT interval, but vortioxetine did not prolong QT in a study at doses up to 40 mg a day. The US Food and Drug Administration (FDA) trazodone label warning about QT-prolonging drugs therefore does not apply to this pair (trazodone FDA label; vortioxetine EMA SmPC and FDA label). Both drugs can lower blood sodium, and the risk is higher in older people (vortioxetine SmPC, EMA; trazodone FDA label). Vortioxetine does not inhibit cytochrome P450 (CYP) enzymes, including CYP3A4, which forms the active metabolite of trazodone in the liver. The documents report no pharmacokinetic study of this pair (vortioxetine SmPC, EMA; trazodone SmPC, AEMPS).
Symptoms
Serotonin syndrome presents with agitation, hallucinations, a fast pulse, unstable blood pressure, fever, overactive reflexes, poor coordination, nausea, vomiting and diarrhoea (vortioxetine summary of product characteristics, SmPC, European Medicines Agency, EMA). Trazodone causes somnolence and a drop in blood pressure on standing, sometimes with fainting, more often in older people (trazodone SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). Low blood sodium causes headache, difficulty concentrating, memory problems, confusion, weakness and unsteadiness that can lead to falls. Severe cases bring hallucinations, fainting and seizures (trazodone label, US Food and Drug Administration, FDA).
Management
No document contraindicates this combination or says to avoid it, so use it with monitoring (trazodone summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS; vortioxetine SmPC, European Medicines Agency, EMA). The UK National Institute for Health and Care Excellence (NICE) allows adding an antidepressant from a different class when depression has had no response or a limited response to an antidepressant. NICE also advises considering referral to a specialist mental health service or consulting a specialist, and explaining to the patient in advance that side effects may increase (NICE NG222). Monitor for serotonin syndrome and neuroleptic malignant syndrome, particularly at the start of treatment (vortioxetine SmPC, EMA; trazodone label, US Food and Drug Administration, FDA). If either appears, stop both drugs at once and start symptomatic treatment (vortioxetine SmPC, EMA; trazodone SmPC, AEMPS). Somnolence and orthostatic hypotension from trazodone can add to the effects of other psychotropic drugs, especially in older people. Warn the patient or carer and watch these effects closely after the start and before and after each dose increase (trazodone SmPC, AEMPS). Use vortioxetine with caution together with drugs that lower sodium, trazodone included, especially in older people (vortioxetine SmPC, EMA; trazodone FDA label). In symptomatic hyponatraemia, stop trazodone, consider stopping vortioxetine and start treatment (trazodone FDA label; vortioxetine SmPC, EMA).
Your whole list in one report
Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email
Add more drugsMedicine list: everything you take in one place →
Sources
- AEMPS: Ficha técnica: Trazodona (nº registro 78585), sección 4.5 (2026)– AEMPS, CIMA, nº registro 78585 (Trazodona Normon 100 mg), revisión 06/2026, secciones 4.4 y 4.5
- FDA: RALDESY (trazodone hydrochloride) prescribing information (2026)– FDA, DailyMed setid 34708cc1-b0b2-4fd0-b9f3-7f008b457fc9 (Validus), revisión 09/2026 (versión 6), secciones 5.2, 5.3, 5.9 y 7
- NICE: Depression in adults: treatment and management (NG222), further-line treatment (2022)– NICE guideline NG222, published 06/2022, recommendations 1.9.8–1.9.9 (adding trazodone to an SSRI as a further-line option)
- EMA: Ficha técnica: Vortioxetina – Brintellix (EU/1/13/891), sección 4.4 (2026)– EMA, SmPC Brintellix (EU/1/13/891), texto en CIMA nº 113891010, información del producto actualizada 19/01/2026, secciones 4.3, 4.4, 4.5 y 5.1
- FDA: TRINTELLIX (vortioxetine) prescribing information (2025)– FDA, DailyMed setid 239215eb-be32-4286-9677-1e5556c6cccf (Takeda), revisión 02/2025 (versión 4, DailyMed 04/2026), secciones 5.2, 7.1, 7.2 y 12.2